Brokerages Set Cardlytics, Inc. (NASDAQ:CDLX) PT at $6.42

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been given an average rating of “Hold” by the seven research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $6.42.

Several research firms have recently weighed in on CDLX. Lake Street Capital cut their target price on shares of Cardlytics from $5.00 to $3.00 and set a “hold” rating for the company in a report on Thursday, March 13th. Evercore ISI lowered their target price on shares of Cardlytics from $4.00 to $3.00 and set an “in-line” rating on the stock in a research note on Thursday, March 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Thursday, March 13th.

Cardlytics Stock Up 6.4 %

Shares of CDLX opened at $2.48 on Friday. The company has a market capitalization of $129.17 million, a price-to-earnings ratio of -0.41 and a beta of 1.62. Cardlytics has a 52 week low of $1.77 and a 52 week high of $20.52. The stock’s 50-day moving average price is $2.90 and its 200-day moving average price is $3.44. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40.

Insider Activity

In related news, CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.67, for a total value of $32,494.18. Following the sale, the chief financial officer now directly owns 121,976 shares in the company, valued at approximately $447,651.92. The trade was a 6.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Amit Gupta sold 46,857 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $159,313.80. Following the sale, the chief executive officer now owns 418,637 shares of the company’s stock, valued at approximately $1,423,365.80. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,454 shares of company stock worth $391,864 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cardlytics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Atom Investors LP acquired a new stake in shares of Cardlytics in the third quarter valued at approximately $33,000. Tallon Kerry Patrick acquired a new stake in shares of Cardlytics in the 4th quarter worth $37,000. ProShare Advisors LLC purchased a new position in shares of Cardlytics during the 4th quarter worth $43,000. Intech Investment Management LLC acquired a new position in Cardlytics in the 3rd quarter valued at about $47,000. Finally, Virtu Financial LLC acquired a new stake in shares of Cardlytics during the 4th quarter worth approximately $62,000. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.